SWISS BIOTECH SUCCESS STORY





- Family-owned biopharmaceutical group of companies
 Founded in 1979 by Rolland-Yves Mauvernay
- Identifies high-potential compounds for in-licensing, conducts clinical development and commercializes its treatments through partners across the globe
 - Aims to develop innovative therapies that target high unmet medical needs in oncology



THE PRESIDENT







EXPERTISE

- Clinical development
- Translational medicine
 - CMC
 - Regulatory affairs

Each year



Patients benefit from our innovations



Compounds registered

OXALIPLATIN & TRIPTORELIN



INDICATIONS

- Colorectal-, pancreatic & gastric cancers
- Advanced prostate cancer
- Endometriosis, paraphilia, central precocious puberty



PIPELINE

From preclinical to phase II

5 Pro

Products for **oncology**



Products for infectious diseases

DEBIO 1143 HEAD & NECK CANCER — PHASE III READY

AFABICIN BONE & JOINT INFECTIONS — PHASE II

DEBIO 1347 TISSUE AGNOSTIC FGFR FUSIONS ———— PHASE II

DEBIO 1562 DIFFUSE LARGE B-CELL LYMPHOMA ———— PHASE II

DEBIO 1124 MEDULLARY THYROID CANCER ———— PHASE I

debiopharm.com/pipeline



- **★** Completed achievement with lasting impact
- **★** Strong impact on society
- roduct approval and sustainable revenues
- **★** Important IP, innovative deal-making, acquisition
- Involvement of one or more Swiss citizens
- **★** Swiss-based company/institution
- **Creation of jobs in Switzerland**
- **Swissness: Think global, made in Switzerland**

Organized by



